A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.

Details

Serval ID
serval:BIB_1EA7E9E28F84
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Journal
Acta Oncologica (stockholm, Sweden)
Author(s)
Gallerani E., Bauer J., Hess D., Boehm S., Droege C., Jeckelmann S., Miani M., Herrmann R., Marsoni S., Sperka S., Sessa C.
ISSN
1651-226X (Electronic)
ISSN-L
0284-186X
Publication state
Published
Issued date
2011
Volume
50
Number
7
Pages
1105-1110
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Abstract Background. The broad spectrum of antitumor activity of both the oral platinum analogue satraplatin (S) and capecitabine (C), along with the advantage of their oral administration, prompted a clinical study aimed to define the maximum tolerated dose (MTD) of the combination. Patients and methods. Four dose levels of S (mg/m(2)/day) and C (mg/m(2)/day) were evaluated in adult patients with advanced solid tumors: 60/1650, 80/1650, 60/2000, 70/2000; a course consisted of 28 days with sequential administration of S (days 1-5) and C (days 8-21) followed by one week rest. Results. Thirty-seven patients were treated, 24 in the dose escalation and 13 in the expansion phase; at the MTD, defined at S 70/C 2000, two patients presented dose limiting toxicities: lack of recovery of neutropenia by day 42 and nausea with dose skip of C. Most frequent toxicities were nausea (57%), diarrhea (51%), neutropenia (46%), anorexia, fatigue, vomiting (38% each). Two partial responses were observed in platinum sensitive ovarian cancer and one in prostate cancer. Conclusion. At S 70/C 2000 the combination of sequential S and C is tolerated with manageable toxicities; its evaluation in platinum and fluorouracil sensitive tumor types is worthwhile because of the easier administration and lack of nephro- and neurotoxicity as compared to parent compounds.
Pubmed
Web of science
Create date
18/02/2011 10:49
Last modification date
20/08/2019 12:54
Usage data